For retatrutide , the 2023 New England Journal of Medicine phase 2 trial used doses of up to 12 mg weekly, with a structured escalation schedule beginning at lower doses and increasing incrementally over a period of weeks
Its incredibly important that you do your research and stay informed about new compounds and the claims made about them, as the goal is to improve your healthspan, not reduce it
Topical cosmetic use appears to be well tolerated for most individuals, though long-term systemic applications have not been fully studied
Secondary hypogonadism is due to abnormal signaling from the hypothalamus or pituitary gland and is marked by low testosterone without a rise in LH levels
The most common experiences include slight nausea (particularly with first doses), minor fatigue or drowsiness, temporary dizziness, injection site reactions like mild redness or itching, and sleep disturbances (usually with evening dosing)
The GHK-Cu peptide treatments typically run in 30-day cycles, often 15 days on and 15 days off